CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices

Host: Charles Turck, PharmD, BCPS, BCCCP <br> Guest: Samuel Yamshon, MD <br> <p>The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.</p>